AegisCN LLC
AegisCN LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute neurological injury and stroke. The company’s lead therapeutic candidate, CN-105, is a proprietary neuroprotective peptide designed to reduce inflammation, limit secondary brain injury, and improve recovery following central nervous system events. AegisCN’s development efforts have centered on high-impact medical conditions with significant unmet need, including intracerebral hemorrhage (hemorrhagic stroke) and traumatic brain injury (TBI). CN-105 has advanced through Phase 1 and Phase 2 clinical studies, reflecting the company’s commitment to translating cutting-edge neuroscience into real-world treatment options for patients and providers.
Industries
Nr. of Employees
small (1-50)
Awards
Candidate Acute Traumatic Brain Injury (TBI) Management Capabilities (CATMC) and Acute TBI Diagnostics and Monitoring (ATDM) in Austere Environments
Development of CN-105, a novel neuroprotective peptide, for Treatment of Traumatic Brain Injury
Funding (ceiling)
$826,332
Award Year
2021
Key People
Robert Fremeau
Vice President, R&D
Maureen Maughan
Vice President, Drug Development
Robert Fremeau
Vice President, R&D
Maureen Maughan
Vice President, Drug Development